Silencing Lyn kinase overcomes resistance to imatinib in Bcr-Abl-dependent CML cells

被引：0
|
作者：
Wu, Ji Yuan [1 ]
Talpaz, Moshe [1 ]
Donato, Nicholas J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2345
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Human CML stem cells insensitive to imatinib even when BCR–ABL is inhibited
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2011, 8 (3) : 126 - 126
  • [22] Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients
    Rossignol, Alexis
    Levescot, Anais
    Jacomet, Florence
    Robin, Aurelie
    Basbous, Sara
    Giraud, Christine
    Roy, Lydia
    Guilhot, Francois
    Turhan, Ali G.
    Barra, Anne
    Herbelin, Andre
    Gombert, Jean-Marc
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (07) : 1870 - 1875
  • [23] BCR-ABL kinase domain mutations in the P-loop and at imatinib contact sites in CML patients with imatinib resistance are associated with higher maximum imatinib doses
    Pelz-Ackermann, Oliver
    Deininger, Michael W. N.
    Cross, Michael
    Wildenberger, Kathrin
    Krahl, Rainer
    Wang, Song-Yau
    Ai-Ali, Haifa K.
    Niederwieser, Dietger W.
    Lange, Thoralf
    BLOOD, 2007, 110 (11) : 858A - 858A
  • [24] AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE
    Pennisi, M. S.
    Stagno, F.
    Massimino, M.
    Stella, S.
    Di Raimondo, F.
    Messina, A.
    Vigneri, P.
    HAEMATOLOGICA, 2008, 93 : S66 - S66
  • [25] AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE
    Vigneri, P.
    Stagno, F.
    Massimino, M.
    Berretta, S.
    Stella, S.
    Del Fabro, V.
    Messina, A.
    Di Raimondo, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 312 - 313
  • [26] BCR- ABL KINASE MUTATIONS TO IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA
    Thungappa, S. Chiradoni
    Singh, T.
    Rashmi, N. R.
    Lokanatha, D.
    Rajshekar, H.
    Lakshmaiah, K. C.
    Babu, K. G.
    Suresh, T. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 357 - 357
  • [27] Inhibition of Autophagy to Overcome Imatinib Resistance Regardless of BCR-ABL Expression in Philadelphia-Positive CML Cells
    Yoo, E. S.
    Ahn, J-Y.
    Yang, J-Y.
    Mun, Y-C.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S383 - S383
  • [28] Allosteric Bcr-Abl Inhibitor ABL001 Overcomes Bcr-Abl Tyrosine Kinase Inhibitor Resistance and Enhances MDM2 Inhibitor CGM097 Activity in Blast Crisis CML Cells
    Tao, Wenjing
    Mak, Po Yee
    Andreeff, Michael
    Carter, Bing Z.
    BLOOD, 2017, 130
  • [29] The dual-specific Src and Abl kinase inhibitor (SAKI) CGP76030 overcomes imatinib mesylate resistance in murine bone marrow cells transformed by Bcr-Abl.
    Simon, N
    Susanne, C
    Hallek, MJ
    BLOOD, 2003, 102 (11) : 860A - 860A
  • [30] The significance of BCR-ABL dependent EpCAM expression for treatment resistance in CML
    Towhidi, Tara
    Zhuang, Ruimeng
    Juecker, Manfred
    Boddu, Vijay Kumar
    Gires, Oliver
    Busch, Hauke
    Illert, Lena
    Duyster, Justus
    Gemoll, Timo
    Gieseler, Frank
    von Bubnoff, Nikolas
    Gorantla, Sivahari Prasad
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 144 - 144
12345